Nasus Pharma Ltd. announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup Inc. to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma's intranasal powder epinephrine product candidate. The collaboration establishes a comprehensive framework to support the development of NS002 through regulatory submissions with both the U.S. Food and Drug Administration (the "FDA") and the European Medicines Agency (the "EMA"). This strategic relationship provides Nasus with access to Aptar's technical expertise and manufacturing capabilities to advance NS002 through current clinical development to commercialization in alignment with Nasus Pharma's timeline and objectives.
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
